HC Wainwright Comments on Pharming Group’s FY2025 Earnings (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR) – Research analysts at HC Wainwright lowered their FY2025 EPS estimates for shares of Pharming Group in a report released on Tuesday, October 15th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.60 for the year, down from their prior forecast of $0.65. HC Wainwright currently has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.15) per share.

Pharming Group Stock Down 0.2 %

PHAR opened at $8.68 on Wednesday. Pharming Group has a 52 week low of $6.65 and a 52 week high of $13.20. The business has a 50 day moving average price of $7.90 and a two-hundred day moving average price of $8.64. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40. The company has a market cap of $584.55 million, a PE ratio of -54.25 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The business had revenue of $74.09 million during the quarter, compared to analyst estimates of $71.95 million. During the same period in the previous year, the firm earned $0.02 earnings per share.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.